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Abstract
The burden of infection in industrialized countries has prompted
considerable effort to improve the outcomes of patients with
sepsis. This has been formalized through the Surviving Sepsis
Campaign ‘bundles’, derived from the recommendations of 11
professional societies, which have promoted global improvement in
those practices whose primary goal it is to reduce sepsis-related
death. However, difficulties remain in implementing all of the
procedures recommended by the experts, despite the apparent
pragmatism of those procedures. We summarize the main
proposals made by the Surviving Sepsis Campaign and focus on
the difficulties associated with making a proper diagnosis and
supplying adequate treatment promptly to septic patients.
Introduction
Severe sepsis and septic shock are currently among the most
common causes of morbidity and mortality in intensive care,
and their incidences have increased during the past decade
as the population has aged [1,2]. The emergency department
(ED), where patients are treated for community-acquired
infection, many of whom require intensive care unit (ICU)
management [3], has been identified as a setting in which
these syndromes and their outcomes may readily be
observed.
Despite dramatic improvements in diagnostic and treatment
procedures, mortality rates among patients with sepsis
remained unchanged from the 1960s through to the late
1990s. Diagnostic algorithms have therefore been developed
to identify at-risk populations, and professional societies have
worked to implement treatment procedures that focus efforts
on early intervention. The Surviving Sepsis Campaign
proposed management procedures that differentiate between
‘resuscitation bundles’ for the first 6 hours and ‘management
bundles’ to be applied until the end of the 24th hour [4].
These procedure recommendations have been disseminated
worldwide and are focused on global improvement in
practices whose primary goal it is to reduce sepsis-related
death. As a consequence of the recommendations, a trend
toward decreasing mortality has been observed during the
past few years.
Difficulties remain, however, in applying all of the procedures
recommended by the experts. This article summarizes the
main proposals raised by the Surviving Sepsis Campaign and
focuses on the difficulties associated with applying these
guidelines in an appropriate time frame.
Diagnosis of sepsis and severity assessment
Definitions of sepsis, severe sepsis, and septic shock were
proposed 15 years ago. They were based on expert advice
and used criteria that identify progression of the infection
along with appropriate responses [5]. However, these criteria
are clearly inadequate in terms of allowing detection of severe
infections in routine daily practice. A study of a large
multicenter cohort of ICU patients with infection [6] conclu-
ded that simply categorizing an infectious process as ‘sepsis’
or ‘severe sepsis’ did not predict prognosis. A high score
indicating a septic condition did not necessarily predict a
patient’s outcome, even though that outcome might be
affected by sepsis-related organ dysfunction.
With regard to patients presenting at the ED because of
community-acquired pneumonia (CAP), a recent report from
Dremsizov and coworkers [7] illustrated the limited value of
the well established criteria for ‘systemic inflammatory
response syndrome’ (SIRS) in predicting outcome. That work
emphasizes the inability of the SIRS designation to identify
which infected patients were at risk for developing severe
sepsis or shock. These findings prompted experts to propose
new scoring systems aimed at identifying patients who are at
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risk for developing severe conditions related to infection.
Shapiro and coworkers developed the Mortality in Emergency
Department Sepsis (MEDS) score to predict 28-day [8] and
1-year [9] outcomes in patients presenting at an ED with
infection, and calculation of this score requires data that are
immediately available in the ED. Despite its ability to predict
all-cause death in the study population, the accuracy of the
MEDS score has not been tested at the individual patient
level; its use at the bedside has not been evaluated, and
therefore this tool should not be used in decisions regarding
triage and ICU referral [10]. Most of the other newly
developed scoring systems appear to have only marginal
utility in daily routine practice because they require
microbiologic identification and 24-hour clinical evaluation;
hence, they lack the immediacy that is required for decision
making in emergency medicine [6]. To date, the Pneumonia
Severity Index is the only scoring system that is considered to
help physicians to assess severity of illness in the ED [11].
Using this score at the bedside allows better triage of low-
risk patients [12-14], but it does not alter outcomes in more
severe pneumonia [15], in which it is only slightly more
effective than the inadequate SIRS classification [7].
Evaluation of biologic factors also may help in determining the
severity of illness. Cady and coworkers [16] proposed use of
the arterial blood lactate level to identify patients with severe
illness and to assess the severity of sepsis. The Surviving
Sepsis Campaign Management Guidelines Committee [4],
and the American College of Chest Physicians and the
Society of Critical Care Medicine Consensus Conference
Committee [17] have also proposed guidelines that help to
identify those patients who are at greater risk for sepsis.
Recent reports from Shapiro [18] and Nguyen [19] and their
colleagues have emphasized the importance of lactate
clearance in identifying those patients who will respond to
treatment and have a favorable outcome. Lactate clearance
was shown to be a better prognostic factor than a single
lactate determination performed on ED admission [18,19].
However, a single venous lactate measurement above 4
mmol/l predicted short-term and in-hospital risk for death in
patients presenting at the ED with suspected infection [20],
even in those with normal arterial blood pressure [21]. A
single lactate dosage is thus a valuable tool that may facilitate
early detection of at-risk patients. Plasma procalcitonin may
also be valuable in this setting. Procalcitonin is a more
specific test than C-reactive protein [22] and interleukin-6,
and can help the physician to detect sepsis [23]. Higher
levels of procalcitonin are sufficiently specific to identify those
septic patients who will develop severe sepsis, but it is not
sensitive enough for routine use in ED triage [24].
Antibiotics: fast and fitted
It is clear that the site of infection should be managed
promptly in patients with severe infection, including emer-
gency surgery when applicable. However, efforts should also
focus on early and carefully controlled antimicrobial therapy.
Minimizing the delay between admission and beginning anti-
microbial treatment is key to achieving a successful outcome.
The potential influence of delayed antibiotic therapy was first
evaluated in patients with CAP. In a series of 18,209
Medicare patients older than 65 years admitted because of
CAP [25], the antibiotic regimen used saved lives when the
first dose was administered before hour 4 after admission. Of
note, fewer than 50% of patients received antibiotics during
the first 4 hours in this study and as many as 17% received
antimicrobial treatment after hour 6. Those patients in whom
administration of antimicrobial agents was delayed were
elderly people with an atypical CAP presentation, or they
exhibited clinical features inconsistent with a diagnosis of
sepsis, such as the absence of fever and altered mental
status [26] (specifically, patients in whom the diagnosis of
infection was not obvious). Such a lack of aggressive and
early antimicrobial therapy has been identified in various
settings in which patients were being treated for such
conditions as meningitis, cancer, CAP, and nosocomial
pneumonia [27-33]. A recent retrospective analysis quantified
the impact of delayed antimicrobial treatment in patients with
severe sepsis. Kumar and coworkers [34] demonstrated that
every additional hour without antibiotics increased the risk for
death in hypotensive septic patients by 7.6% during the first
6 hours. Early antibiotic therapy has been incorporated into
the Surviving Sepsis Campaign recommendations [35], and
we expect compliance with this component of the guidelines
to increase from its current low level [36].
The focus of infection is sometimes difficult to ascertain, but
treatment must effectively target the responsible pathogen,
from among a wide range of potentially etiologic agents [37].
Initial selection of an antimicrobial agent with good activity
against the causative organism is crucial for survival. A
prospective evaluation of sepsis [38] emphasized that, other
than comorbidity, the factor most strongly associated with
death was ineffectiveness of antimicrobial treatment against
the micro-organism identified in blood cultures. Several large
reports corroborated the relation between ineffective anti-
biotic treatment and poor prognosis. Consequently, broad-
spectrum antibiotics have been recommended, and the agent
selected should provide coverage against the micro-
organisms that are usually involved in the suspected focus of
infection [35]. Supportive clinical evidence for use of broad-
spectrum antibiotics will probably remain sparse [36], but
effective antimicrobial management requires good micro-
biologic sense.
Adherence to such guidelines regarding use of antibiotics
may positively influence prognosis [39], but efforts to improve
detection of pathogens should continue because enhanced
specificity allows one to focus treatment on the responsible
micro-organism and so limit the spectrum of coverage. The
usual microbiologic techniques of detection may lack
effectiveness. The use of urine antigens to StreptococcusPage 3 of 8
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pneumoniae and Legionella pneumophila type 1 can help in
patients with pneumonia. Apart from their good sensitivity, the
presence of these antigens can be detected long after an
infection and, in the case of pneumoccocal related infection,
may reflect carriage of the micro-organism in the upper
respiratory tract [40]. Sensitive genomics tools are now
available to detect both bacteria and viruses, and multiplex
platforms allow screening of a wide range of micro-organisms
[41]. The position of these techniques in the diagnostic
armamentarium is yet to be defined, but efforts to improve
antimicrobial therapy must continue so that our practices and
therefore outcomes may be improved in the future.
Fluid loading
Among the symptomatic treatments, need for hemodynamic
management is the most apparent, but modalities continue to
be discussed and the scientific literature abounds with
studies in this area. Efficient restoration of circulating blood
volume is the primary goal of resuscitation in septic patients
[42]. Albumin was the first product to be broadly used for
intravenous fluid loading, but a meta-analysis comparing
albumin with other fluid loading agents [43] identified an
increased risk for death among patients who received
albumin for supportive treatment during shock. However,
subgroup analysis (septic patients with hypoalbuminemia)
[44] revealed a trend toward greater efficiency of fluid loading
with albumin. The cost-benefit balance is another factor that
has restricted use of albumin, but in their recent report
Guidet and colleagues [45] indicated that albumin infusion
was potentially cost-effective in patients with sepsis. Thus,
use of albumin should be considered with caution; it currently
lacks the support needed for it to be recommended for use in
patients with septic shock.
Transfusion of packed red cells may also be considered in
septic patients because transfused hemoglobin may contri-
bute to improved oxygen transport and delivery. Few
controlled studies have tested this option, however, and it has
been reported that liberal transfusion is potentially ineffective
[46,47]. Since the publication of the findings of Rivers and
coworkers [48], use of packed red cells has been regarded
as a valuable approach to improving tissue oxygenation, but
the specific indications for transfusion of packed red cells in
this setting remain unclear.
Although controversy persists in this area, preferential use of
crystalloids rather than colloids is supported by the available
literature. For the same amount of volume expansion, there is
no difference between these two treatments in terms of
ejection stroke volume or oxygen delivery [49]. Systematic
reviews and meta-analyses that included patients with sepsis
and other types of patients concluded that crystalloids and
colloids were generally similar in effect; an exception was one
study that identified an advantage for crystalloids [50]. This
finding received support from a randomized trial [51] that
found that patients with septic shock receiving colloids had
greater renal impairment. A recent study [52] was conducted
to compare colloid with crystalloid volume resuscitation, with
the aim being to identify the safest choice for use in patients
with sepsis. This study, which employed a prospective
randomized multicenter design, compared the influence on
outcome of Ringer’s lactate versus hydroxyethyl starch and of
intensive versus conventional insulin therapy in patients with
severe sepsis and septic shock. Experts have already
criticized this study on the grounds that its design confounds
applicability of the findings to routine daily care [53]. To
summarize, although infusing fluids is a cornerstone of
supportive care during sepsis, the optimal modalities and
volume are difficult to determine and choices should be
driven by objectives in the individual patient [48].
Vasoactive drugs
A solid rationale explains the utilization of vasopressors in
daily practice [54], but the few comparative studies and the
combination of different molecules account for their practical
selection. Combining norepinephrine (noradrenaline) and
dobutamine improved hemodynamic parameters of
hepatosplanchnic circulation [55] but required invasive
monitoring procedures, without clinical benefit. Dopamine
and epinephrine are vasoconstrictors that also increase
cardiac output, but their metabolic effects may be harmful
[56,57]. In addition, use of vasopressors has been
associated with poorer outcomes in septic patients, but their
influence on mortality was unclear [58].
To assist physicians in their use of vasoactive drugs,
professional associations have proposed guidelines that
allow an opportunity to administer epinephrine or a
combination of norepinephrine and dobutamine to more
severely ill patients [4]. A recently reported study [59]
indicated that these two strategies were equivalent in terms
of both efficacy and safety. Interest in vasopressin is reflected
in a growing number of publications, but the available
evidence does not allow its integration into a global
therapeutic scheme. However, recent data [60] may justify
reconsideration of vasopressin in severe sepsis management
guidelines in the near future. The VAsopressin in Septic
Shock Trial (VASST) study [61] is currently comparing
vasopressin with norepinephrine as initial vasopressor in
septic shock patients. Because the study is not yet
completed, no analysis or definite conclusions can yet be
drawn from this trial.
Whichever drug is selected, introduction of vasopressors
should be considered after optimal fluid loading; these
agents may allow therapies to be applied earlier and more
aggressively in order to improve physiological parameters and
ultimately outcomes [48,62].
Applying early goal-directed therapy
In the initial management of patients with sepsis, improving
physiological parameters such as blood pressure and tissue
Available online http://ccforum.com/content/11/S5/S2oxygen delivery is a clear goal, as has been emphasized by
experts since the late 1990s [63]. Previous studies
underscored that applying an early goal-directed therapy
(EGDT) approach could improve survival. The landmark study
conducted by Rivers and coworkers [48] emphasized this
concept in the field of sepsis. Its publication in 2001
prompted a debate in basic medical practice centered on the
question, is it possible to improve outcomes in septic patients
by increasing tissue oxygenation parameters during the first 6
hours of management?
The protocol proposed by Rivers and coworkers involves
attainment of physiological levels of hemodynamic para-
meters (arterial blood pressure and central venous oxygen
saturation [ScvO2], by using fluid loading, vasopressors,
packed red cells, and early initiation of mechanical ventilation)
as rapidly as possible. The overwhelmingly positive results of
this EGDT study prompted a number of ED and ICU teams to
change their daily care in accordance with the study protocol.
Some papers [62,64-66] reported partial or absolute
adherence to the procedures evaluated by Rivers and
coworkers. Others proposed adapting the procedure to their
medical system with either less aggressive therapy or by
forming ‘sepsis teams’ specifically tasked with managing
patients with severe infection [67-72]. The overall result of
these reports was a trend toward improved outcomes in
septic patients [73].
However, these findings have been tempered by a number of
barriers. Not all EDs have access to the same equipment, and
ability to monitor hemodynamic parameters invasively varies
widely [74]. Another unresolved issue is that not all ED
physicians have the necessary resuscitation skills to
administer optimal treatment, as observed in ICUs [75].
Additionally, a number of recent reports have identified the
fact that EDs are increasingly overburdened. This can
compromise the quality of care delivered to patients,
especially those who require highly technical care that many
ED physicians do not have time to practice because of ever-
increasing numbers of patients [76-78].
Finally, studies are now emerging that indicate how few of the
recommendations have been implemented. Early admini-
stration of antimicrobial therapy was poorly adhered to, even
in recent reports. In these, although the Surviving Sepsis
Campaign proposals were implemented, the mean delay to
first infusion of antibiotics remained in excess of 3 hours [62],
and as many as 68% of patients did not receive their first
dose within this period [79]. Only a few EGDT validation
studies have been conducted in EDs applying aggressive
treatment outside the ICU. However, even in those EDs,
mortality sometimes remained at 31% before and after the
institution of procedures to improve coordination between ED
and ICU [80]. In addition, effort should be maintained after
the initiation of an EGDT strategy because performance
dramatically decreased after initial implementation [81,82].
In addition to the pragmatism of this therapeutic approach,
the optimal tools with which to evaluate attainment of
physiological goals have also been subject to debate.
Although ScvO2 is a valuable parameter when it is abnormal,
it may be in the normal range even in severely septic patients
[73]. The hemodynamic presentation, of which there are
many, depends on comorbidities and stage of sepsis [83]. In
addition to ScvO2, central venous pressure may also provide
useful information. A low central venous pressure indicates
hypovolemia, and a high central nervous pressure with a low
ScvO2 indicates myocardial suppression or mismatch of
supply and demand. In any clinical situation, the findings must
be interpreted alongside other clinical data. Other indicators
may help, and systolic volume and pulse pressure variation of
10% or above also provide valuable information regarding
blood volume [84]. Relatively liberal use of packed red cells
to improve ScvO2 may be offset by its potential harm [46,47]
but in the setting of severe sepsis and septic shock the
theoretical risks appear balanced by the benefits in terms of
tissue oxygenation [85]. Although use of central venous
pressure and ScvO2 to evaluate attainment of physiologic
goals can be debated [73], it is clear that defining reasonable
goals to treat sepsis is important whatever the local
organization and the available means to achieve those
objectives are [86].
Adjunctive therapies
For the past two decades therapeutic trials attempting to
elicit a change in the host response to infection have failed to
improve patients’ conditions despite positive preclinical data
[87-91]. However, the results of two recent studies have led
to a more promising approach to this problem with recom-
binant human activated protein C (rhAPC) and low-dose
steroids. The hemodynamic effects of steroids have been
widely discussed since their use was found to allow early
withdrawal of vasopressor treatment in a prospective double-
blinded, multicenter study [92]. The positive effects of
steroids on adrenergic receptor cycling and sodium and
water balance have been proposed as explanations for this
efficacy. Their anti-inflammatory role as well as their
anticoagulant effect, caused by limiting membrane expression
of tissue factor, may contribute to the clinical benefit. A major
difficulty lies in defining adrenal deficiency in septic shock
patients, and a number of definitions have thus far been used.
A recent retrospective multicenter cohort study conducted by
the Corticus study group [93] emphasized the importance of
cortisol variation after corticotropin stimulation. That study
additionally raised the possibility of a deleterious effect of
etomidate on hormonal response and outcome, a concern
that was previously reported by others [94]. This specific
point is still subject to debate [95]. Efforts are currently being
made to define the best strategy for use of steroids during
sepsis.
The efficacy of rhAPC has been tested in a large multicenter
study, the results of which have been widely debated. This
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in the natural anticoagulant protein C during sepsis, and thus
it limited organ failures and improved the survival of septic
shock patients [96]. Since then a number of studies have
demonstrated that it has additional beneficial effects on
complex interactions with inflammation, innate immunity, and
apoptosis [97,98]. rhAPC also protected animals and healthy
volunteers from hypotension after lipopolysaccharide
challenge. A similar finding was also reported in the
PROWESS (Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis) study, with more rapid
improvement in hypotension and vasopressor withdrawal [99].
These clinical effects could be related to endocrine modulation
(adrenomedullin was implicated in this regard) and vasoactive
capacity. Mechanisms, efficacy, and safety of rhAPC are
discussed in other reviews included in this supplement.
Despite the strong evidence base, use of adjunctive therapies
has remained sparse in the setting of sepsis. Questionnaire
surveys have attested to the under-use of such adjunctive
therapies. Once again, the need for medical adherence to
new therapies must be promoted by implementation of local
guidelines that are inspired by the recommendations of the
Surviving Sepsis Campaign (Figure 1).
Improving standards of care
New standards of care, such as low tidal volume mechanical
ventilation and tight blood glucose control, have recently
emerged and are now a cornerstone of treatment for critically
ill patients. Low tidal volume (≤6 ml/kg) as compared with
‘standard’ mechanical ventilation (12 ml/kg) has improved
survival in patients with acute respiratory distress syndrome
in independent studies [100,101]. Two landmark studies by
van den Berghe and colleagues [102,103] suggested that
aggressive insulin therapy improved 30-day survival in
critically ill surgical patients, and reduced morbidity indicators
such as weaning from mechanical ventilation and hospital
days in medical ICU patients. Whereas occurrence and
management of hypoglycemia appeared irrelevant in the main
papers and additional data, hypoglycemia has been identified
as potentially causing harm by others [104]. Even if these
standards are still discussed and do not specifically impact
on sepsis, they may also contribute to quality-of-care improve-
ment and finally to patients’ successful outcome [83,84].
Conclusion
Guidelines that were proposed through the Surviving Sepsis
Campaign to improve outcome in septic patients are difficult
to apply routinely in most EDs. Attempts to apply these
procedures fully have varied widely; diagnosis may be
problematic because of atypical or unspecific presentations,
biomarkers are of little help at the start of treatment and are
unspecific, supportive treatment often depends on local
supply of resources, and specific devices are often absent in
EDs for initial therapy and monitoring. Even adherence to
early administration of antibiotic therapy is poor, with delays
Available online http://ccforum.com/content/11/S5/S2
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Figure 1
Management of severe sepsis in adults in the absence of an immediate life-threatening condition. ABP, arterial blood pressure; ACTH,
adrenocorticotropic hormone; Hb, hemoglobin; RBC, red blood cell; ScvO2, central venous oxygen saturation; SpO2, pulse oximetry. Reproduced
with permission from Marquis S, Roupie E: Prise en charge précoce du choc septique aux urgences/Early management of septic shock in
emergency department. Rèanimation 2006, 15:507-513.being common. Our goal is now to improve the level of care
by applying evidence-based procedures.
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